Recombinant factor VII (NovoSeven) in intraoperative blood saving during neurosurgical treatment of the brain arteriovenous malformation
نویسندگان
چکیده
منابع مشابه
[Recombinant factor VII (NovoSeven) in intraoperative blood saving during neurosurgical treatment of the brain arteriovenous malformation].
BACKGROUND Cerebral arteriovenous (AV) malformation causes, due to the increased blood flow through a malformation, a massive intraoperative bleeding complicating, so, surgical treatment. The use of intraoperative blood saving apparatus during surgery and a recombinant factor VII-a (NovoSeven) significantly reduce complications during surgical treatment. CASE REPORT We reported a case of surg...
متن کاملIntraoperative neuromonitoring during brain arteriovenous malformation microsurgeries and postoperative dysfunction
To evaluate the effectiveness of intraoperative neuromonitoring (IONM) during arteriovenous malformation (AVM) surgery, we retrospectively analyzed neurologic dysfunction in patients who underwent AVM surgery with (IONM group) and without IONM (non-IONM group). The sensitivity and specificity of short-term neurologic dysfunction were calculated in the IONM group. IONM parameters were obtained i...
متن کاملNewly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
UNLABELLED This case report presents a newly diagnosed congenital factor VII deficiency treated with recombinant activated factor VII (rFVIIa). Congenital factor VII deficiency is a rare autosomal-recessive bleeding disorder that occurs in fewer than 1/500,000 persons. Its presentation can vary from epistaxis to hemarthroses and severe central nervous system bleeding, and correlates poorly with...
متن کاملOff-Label Use of Recombinant Activated Factor VII (NovoSeven®)
NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...
متن کاملFactor Viia (recombinant) (novoseven®) in Trauma
EVIDENCE DEFINITIONS • Class I: Prospective randomized controlled trial. • Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. • Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. • Technology assessment: A technology study which doe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Military Medical and Pharmaceutical Journal of Serbia
سال: 2007
ISSN: 0042-8450,2406-0720
DOI: 10.2298/vsp0702151n